Xavier Badia

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Drug Administration

Multidrug Resistant

Clinical Practice

Top Venues

Orphanet journal of rare diseases

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

International journal of technology assessment in health care

This page only lists publications with an associated author ORCID identifier.

Publications

Xavier Badia, Miguel Ángel Calleja, Vicente Escudero-Vilaplana, Antonio Pérez-Martínez, José Luis Piñana, José Luis Poveda, Joan-Antoni Vallès
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV + PTLD). Orphanet journal of rare diseases 19 (1) (2024)
Xavier Badia, Miguel Ángel Calleja, Vicente Escudero-Vilaplana, Antonio Pérez-Martínez, José Luis Piñana, José Luis Poveda, Joan-Antoni Vallès
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV + PTLD). Orphanet journal of rare diseases 19 (1) (2024)
José Luis Poveda, Claudia Gómez, Alicia Gil, Xavier Badia
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain. Orphanet journal of rare diseases 18 (1) (2023)
José Luis Poveda, Claudia Gómez, Alicia Gil, Xavier Badia
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain. Orphanet journal of rare diseases 18 (1) (2023)
José Luis Poveda, Claudia Gómez, Alicia Gil, Xavier Badia
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain. Orphanet journal of rare diseases 18 (1) (2023)
José Luis Poveda, Claudia Gómez, Alicia Gil, Xavier Badia
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain. Orphanet journal of rare diseases 18 (1) (2023)
José Luis Poveda, Claudia Gómez, Alicia Gil, Xavier Badia
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain. Orphanet journal of rare diseases 18 (1) (2023)
Miguel Ángel Calleja, Xavier Badia
Feasibility study to characterize price and reimbursement decision-making criteria for the inclusion of new drugs in the Spanish National Health System: the cefiderocol example. International journal of technology assessment in health care 38 (1) (2022)
Luis Gros, Alicia Roldán Pérez, Almudena Cabero-Martínez, Nerea Domínguez-Pinilla, Adolfo de la Fuente, Eva González-Barca, María Tasso, Montserrat Torrent, Eva Gallardo, Inés Del Cerro, Ariadna Giró-Perafita, Xavier Badia
Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
Xavier Badia, Tania Vico, John Shepherd, Alicia Gil, José Luis Poveda-Andrés, César Hernández
Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019. Orphanet journal of rare diseases 15 (1) (2020)